Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384609 | 1.00 | ALDH1A1 (0.62) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL9329089 | 1.00 | ALDH1A1 (0.62) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL25190699 | 0.89 | ALDH1A1 (0.51) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL10909091 | 0.81 | GRIN2D (0.68) | ALDH1A1KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL22198126 | 0.81 | GRIN2D (0.68) | ALDH1A1KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL4275683 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL5668373 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL27198359 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL4275687 | 0.80 | KMT2A (0.64) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL9118994 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4EGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021117053-A1 | AN IMPROVED PROCESS FOR PREPARATION OF PURE ALDOXIME | DR. SILVIU PHARMACHEM PVT. LTD. (IN) | 2021-06-17 | — | — | WO | claimed |
| US-20230346903-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | PFIZER INC. (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2021117053-A1 | AN IMPROVED PROCESS FOR PREPARATION OF PURE ALDOXIME | DR. SILVIU PHARMACHEM PVT. LTD. (IN) | 2021-06-17 | — | — | WO | disclosed |
| US-10946086-B2 | Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190142922-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | PFIZER INC. | 2019-05-16 | — | — | US | disclosed |
| CN-104496975-B | Benzimidazole compound containing isoxazole and application of compound | 浙江工业大学 | 2017-01-11 | — | — | CN | disclosed |
| CN-104496975-A | Benzimidazole compound containing oxadiazole and application of compound | UNIV ZHEJIANG TECHNOLOGY | 2015-04-08 | — | — | CN | disclosed |
| CN-104045634-A | Pyrazolecarboxamide compound containing difluoromethyl as well as preparation method and application of pyrazolecarboxamide compound | UNIV ZHEJIANG TECHNOLOGY | 2014-09-17 | — | — | CN | disclosed |
| US-7220768-B2 | Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus | WYETH HOLDINGS CORP. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2004072052-A2 | ISOXASOLE-CONTAINING THIOUREA INHIBITORS USEFUL FOR TREATMENT OF VARICELLA ZOSTER VIRUS | WYETH HOLDINGS CORPORATION (US) | 2004-08-26 | — | — | WO | disclosed |
| US-4988861-A | Device for measuring the energy of an electric arc | SOCIETE ANONYME DITE: COMPAGNIE LYONNAISE DE TRANSMISSIONS OPTIQUES (FR) | 1991-01-29 | — | — | US | disclosed |
| EP-0144885-B1 | METHOD FOR THE SIMULTANOUS PREPARATION OF NITRILES AND ACRYL AMIDE OR METHACRYL AMIDE | BASF Aktiengesellschaft (DE) | 1989-07-26 | — | — | EP | disclosed |
| US-4686302-A | Simultaneous preparation of nitriles and acrylamide or methacrylamide | BASF AKTIENGESELLSCHAFT (DE) | 1987-08-11 | — | — | US | disclosed |
| EP-0112524-B1 | TRICHLOROACRYLOYL OXIME DERIVATIVES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-05-28 | — | — | EP | disclosed |
| US-4581365-A | Trichloroacryloyl oxime fungicides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-04-08 | — | — | US | disclosed |
| EP-0144885-A2 | Method for the simultanous preparation of nitriles and acryl amide or methacryl amide | BASF Aktiengesellschaft (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0112524-A1 | Trichloroacryloyl oxime derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1984-07-04 | — | — | EP | disclosed |
| US-4321369-A | INDOLE DYES | STERLING DRUG INC. (US) | 1982-03-23 | — | — | US | disclosed |
| EP-0035773-A2 | Substituted oximes, process for preparing them and duplicating and marking systems | STERLING DRUG INC. (US) | 1981-09-16 | — | — | EP | disclosed |
| US-4283077-A | PRESSURE SENSITIVE CARBONLESS DUPLICATING SYSTEMS AND THERMAL MARKING SYSTEMS | STERLING DRUG INC. (US) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142922-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | SIGLEC7, SIGLEC9, FCGR3B | ALDH1A1 4380/4885KDM4E 2366/4885GAA 1285/4885 |
| US-10946086-B2 | Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof | SIGLEC7, SIGLEC9, FCGR3B | ALDH1A1 4380/4885KDM4E 2366/4885GAA 1285/4885 |
| US-20230346903-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | SIGLEC7, SIGLEC9, FCGR3B | ALDH1A1 4380/4885KDM4E 2366/4885GAA 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.